VDR rs11568821: Understanding the Cdx2 Binding-Site Variant
The rs11568821 variant is a single nucleotide polymorphism located in the promoter region of the VDR gene, which encodes the vitamin D receptor. It is frequently studied for its potential influence on how the body regulates calcium absorption and its association with bone mineral density traits.
What each genotype means
Cdx2 binding site variant
This genotype is located in the promoter region of the VDR gene, which influences how the vitamin D receptor is expressed. Research has investigated whether this variation affects intestinal calcium absorption and bone mineral density, though evidence regarding its clinical impact remains limited and inconsistent across different populations.
The A allele is found at a frequency of approximately 0.18-0.22 in European populations and up to 0.45 in African populations.
Cdx2 binding site variant
Carrying one copy of each allele means you have a heterozygous profile for this VDR promoter polymorphism. Studies have explored potential links between this variant and bone health or colorectal cancer risk, but current scientific consensus is limited and findings have not been consistently replicated across diverse groups.
This heterozygous genotype is common in many populations, reflecting the combined frequency of the A and G alleles in those ancestral groups.
Cdx2 binding site variant
This genotype represents the alternative homozygous state for the Cdx2 binding-site polymorphism in the VDR promoter. While this region is known to regulate vitamin D receptor activity, the specific influence of this genotype on long-term bone mineral density or disease risk is not well-established and remains a subject of ongoing research.
The frequency of this genotype varies significantly by ancestry, reflecting the underlying distribution of the G allele in global populations.
What is the rs11568821 Variant?
The rs11568821 variant is a specific genetic change located within the promoter region of the VDR gene on chromosome 12. This region is often referred to in scientific literature as the Cdx2 binding-site polymorphism. The promoter region acts as a control switch for the gene, determining how much of the VDR protein is produced by the cell. By sitting in this regulatory area, the variant may influence the binding efficiency of transcription factors, which are proteins that help turn genes on or off. Because the VDR gene is responsible for creating the receptor that allows the body to respond to vitamin D, variations in this promoter region are hypothesized to potentially alter the sensitivity or expression levels of the receptor itself, thereby impacting downstream biological processes related to mineral metabolism.
The Role of the VDR Gene
The VDR gene provides the blueprint for the vitamin D receptor, a protein essential for maintaining calcium and phosphate balance in the body. When the active form of vitamin D, known as calcitriol, binds to this receptor, the resulting complex partners with other proteins to regulate the activity of various vitamin D-responsive genes. This process is critical for the absorption of calcium and phosphate from the intestines into the bloodstream, which in turn supports the development and maintenance of strong bones and teeth. When the VDR protein functions correctly, it ensures that the body can effectively utilize vitamin D to maintain skeletal health. Disruptions or variations in this gene are therefore of significant interest to researchers investigating conditions related to bone density and mineral homeostasis.
Research Associations and Evidence Strength
Research into rs11568821 has primarily focused on its potential link to bone mineral density and fracture risk. While some early studies suggested that the variant might influence transcriptional activity of the VDR gene, the overall evidence remains limited and sometimes conflicting. Large-scale association studies have often struggled to find a consistent, independent effect of this single variant on bone health across diverse populations. Some research has explored its role in colorectal cancer risk or its interaction with dietary calcium and vitamin D intake, but these findings have not been universally replicated. Because bone health is a complex trait influenced by many genes, environmental factors, and lifestyle choices, the impact of this specific SNP is considered modest at best. Consequently, it is not currently used as a reliable clinical predictor for bone-related conditions.
Population Frequency
The frequency of the alleles for rs11568821 varies significantly across different ancestral groups. Data indicates that the A allele frequency is approximately 0.18 to 0.22 in European populations, while it is notably higher, around 0.45, in African populations. These differences highlight the importance of considering genetic ancestry when interpreting population-level data. Because the variant is relatively common in many groups, it is considered a standard polymorphism rather than a rare mutation. Understanding these frequency distributions is essential for researchers who study how genetic variations are distributed globally and how they might contribute to health disparities or variations in physiological traits across different human populations.
What This Information Means for You
It is important to understand that having a specific genotype for rs11568821 does not provide a diagnosis or a definitive prediction of your bone health. Genetic associations are statistical observations made across large groups of people and do not necessarily translate to individual health outcomes. Factors such as diet, physical activity, sun exposure, and overall medical history play a much larger role in determining bone mineral density than this single variant. If you are concerned about your bone health, vitamin D levels, or calcium intake, you should consult with a healthcare professional. They can provide appropriate testing and guidance based on your personal health profile. Never use genetic information to make decisions about supplements or medications without first discussing them with your clinician or pharmacist.
How common is this variant?
The A allele frequency is roughly 0.18-0.22 in European populations and approximately 0.45 in African populations.
Frequently asked questions
Does rs11568821 cause osteoporosis?
No, rs11568821 is not a direct cause of osteoporosis. While it has been studied for potential associations with bone mineral density, it is only one of many factors, and the evidence linking it to clinical disease is limited and inconsistent.
Should I take more vitamin D if I have this variant?
You should not change your vitamin D intake based on this genetic variant. Always consult with your doctor or pharmacist to determine the appropriate vitamin D levels for your specific health needs through blood testing and clinical evaluation.
Is this variant the same as the Cdx2 polymorphism?
Yes, rs11568821 is commonly referred to as the Cdx2 binding-site polymorphism in scientific literature. It is located in the promoter region of the VDR gene where the Cdx2 transcription factor binds.
Can a DNA test tell me if I have weak bones?
A DNA test for a single variant like rs11568821 cannot determine your bone strength. Bone health is a complex trait influenced by genetics, lifestyle, and environment; clinical tools like DEXA scans are used by doctors to assess bone density.
Sources & further reading
Educational information only, last refreshed 10/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11568821?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
Variant in the promoter region (Cdx2 site) of the vitamin D receptor gene associated with altered intestinal calcium absorption and bone mineral density.
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.